----item----
version: 1
id: {74590A44-7E8F-4FEE-B048-D08C495079A4}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/05/29/Abivax launches IPO to fund novel AIDS drug
parent: {9E44CD89-5CEF-43CD-B8D5-C3B05FCA838C}
name: Abivax launches IPO to fund novel AIDS drug
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 14b77516-149f-4856-8aba-655d73561f34

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{728904A1-7259-48E8-8256-60D002A0BFEA}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 43

Abivax launches IPO to fund novel AIDS drug
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 43

Abivax launches IPO to fund novel AIDS drug
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1846

<p>French vaccines and antiviral firm Abivax has launched its initial public offering on Euronext Paris. It is aiming to raise around &euro;50m to fund Phase IIb studies of its small molecule ABX464, which takes a novel approach inhibiting HIV replication, as well as to continue development of ABX203, a Phase IIb/III therapeutic vaccine against chronic hepatitis B.</p><p>Assuming shares are sold at the mid-point of the indicative price range of &euro;18.26-24.34, the company will raise &euro;43.6m, rising to &euro;57.7m if an extension clause and over-allotment option are exercised in full. </p><p>At the upper limit with all additional shares sold, it would raise &euro;65.9m, while at the lower end, with no additional shares sold, it would raise &euro;37.4m. &euro;33m has already been committed from existing investor Truffle Capital and five new investors. The offering will close on 22 June. The price will be determined on 23 June with trading on Euronext commencing on 26 June. </p><p>Abivax was established by Truffle Capital in December 2013 through the merger of three French companies &ndash; Wittycell, Splicos and Zophis &ndash; in collaboration with the Cuban Center for Genetic Engineering and Biotechnology (CIGB). It was founded by its chairman, the French biotech pioneer Dr Philippe Pouletty, and its CEO is Professor Hartmut Ehrlich, former head of R&D at Baxter BioScience.</p><p><b>Related stories</b></p><p><a href="http://www.scripintelligence.com/researchdevelopment/French-biotech-Abivax-IPO-to-fund-antiviral-leader-ambitions-358519" target="_new">French biotech Abivax IPO to fund antiviral leader ambitions</a></p><p><a href="http://www.scripintelligence.com/business/Asia-to-get-cost-competitive-vaccines-from-Abivax-deal-355157" target="_new">Asia to get 'cost competitive' vaccines from Abivax deal</a></p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 371

<p>French vaccines and antiviral firm Abivax has launched its initial public offering on Euronext Paris. It is aiming to raise around &euro;50m to fund Phase IIb studies of its small molecule ABX464, which takes a novel approach inhibiting HIV replication, as well as to continue development of ABX203, a Phase IIb/III therapeutic vaccine against chronic hepatitis B.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 43

Abivax launches IPO to fund novel AIDS drug
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150529T182424
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150529T182424
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150529T182424
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028914
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 43

Abivax launches IPO to fund novel AIDS drug
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358666
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042357Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

14b77516-149f-4856-8aba-655d73561f34
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042357Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
